glucophage XR

DRUG2 trials

Sponsors

Glaser Pediatric Research Network, AstraZeneca

Conditions

Diabetes MellitusObesity

Phase 1

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR

CompletedNCT01192152

AstraZenecaDiabetes Mellitus

Start: 2009-11-30End: 2009-12-31Updated: 2015-05-12

Phase 2

Glaser Obesity Study

Glaser Pediatric Research NetworkObesity

Start: 2003-10-31End: 2007-11-30Target: 76Updated: 2006-10-05

Related Papers

Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.

2011-01-0117 citations

Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up.

2010-02-0189 citations

Relation of body fat indexes to vitamin D status and deficiency among obese adolescents.

2009-07-29121 citations